Abbott Laboratories' (ABT) CEO Robert Ford on Q3 2021 Results - Earnings Call Transcript

Oct. 20, 2021 1:11 PM ETAbbott Laboratories (ABT)1 Comment
SA Transcripts profile picture
SA Transcripts

Abbott Laboratories (NYSE:ABT) Q3 2021 Earnings Conference Call October 20, 2021 9:00 AM ET

Company Participants

Robert Ford – CEO

Scott Leinenweber – Vice President

Bob Funck – Executive Vice President

Conference Call Participants

Robbie Marcus – JPMorgan

Bob Hopkins – Bank of America

Josh Jennings – Cowen

Larry Biegelsen – Wells Fargo

Cecilia Furlong – Morgan Stanley

Vijay Kumar – Evercore ISI

Matt Miksic – Credit Suisse


Good morning, and thank you for standing by. Welcome to Abbott 's Third Quarter 2021 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer portion of this call. [Operator Instructions] This call is being recorded by Abbott.

With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. They cannot be recorded or rebroadcast without Abbott's expressed written permission.

I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing and Acquisition.

Scott Leinenweber

Good morning, and thank you for joining us. With me today are Robert Ford, President and Chief Executive Officer, and Bob Funck, Executive Vice President Finance and Chief Financial Officer. Robert and Bob will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including expected financial results for 2021.

Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A Risk Factors to our Annual Report on Form 10-K for the year ended December 31, 2020.

Abbott undertakes no obligation to

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.